Archived Press Releases
11.30.08 Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
11.06.08 Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
09.04.08 Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents
09.03.08 Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
08.19.08 Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
08.04.08 Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
06.24.08 Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
05.06.08 Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University
04.17.08 GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop microRNA Targeted Therapeutics to Treat Inflammatory Diseases
02.11.08 Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
